2298 related articles for article (PubMed ID: 20231676)
1. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
Wen PY; Macdonald DR; Reardon DA; Cloughesy TF; Sorensen AG; Galanis E; Degroot J; Wick W; Gilbert MR; Lassman AB; Tsien C; Mikkelsen T; Wong ET; Chamberlain MC; Stupp R; Lamborn KR; Vogelbaum MA; van den Bent MJ; Chang SM
J Clin Oncol; 2010 Apr; 28(11):1963-72. PubMed ID: 20231676
[TBL] [Abstract][Full Text] [Related]
2. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
Vogelbaum MA; Jost S; Aghi MK; Heimberger AB; Sampson JH; Wen PY; Macdonald DR; Van den Bent MJ; Chang SM
Neurosurgery; 2012 Jan; 70(1):234-43; discussion 243-4. PubMed ID: 21593697
[TBL] [Abstract][Full Text] [Related]
3. Response assessment challenges in clinical trials of gliomas.
Wen PY; Norden AD; Drappatz J; Quant E
Curr Oncol Rep; 2010 Jan; 12(1):68-75. PubMed ID: 20425610
[TBL] [Abstract][Full Text] [Related]
4. Comparing the volume of gliomas in the brain in FLAIR and post-contrast T1-weighted MRI sequences.
Gurwara S; Azzawe A; Jacobs S; Ravi A; Hardjasudarma M; Toledo EG
J La State Med Soc; 2010; 162(5):265-6. PubMed ID: 21141258
[TBL] [Abstract][Full Text] [Related]
5. Response assessment in neuro-oncology.
Quant EC; Wen PY
Curr Oncol Rep; 2011 Feb; 13(1):50-6. PubMed ID: 21086192
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-tensor imaging for glioma grading at 3-T magnetic resonance imaging: analysis of fractional anisotropy and mean diffusivity.
Lee HY; Na DG; Song IC; Lee DH; Seo HS; Kim JH; Chang KH
J Comput Assist Tomogr; 2008; 32(2):298-303. PubMed ID: 18379322
[TBL] [Abstract][Full Text] [Related]
7. Response Assessment in Neuro-Oncology Clinical Trials.
Wen PY; Chang SM; Van den Bent MJ; Vogelbaum MA; Macdonald DR; Lee EQ
J Clin Oncol; 2017 Jul; 35(21):2439-2449. PubMed ID: 28640707
[TBL] [Abstract][Full Text] [Related]
8. Selection of response criteria for clinical trials of sarcoma treatment.
Schuetze SM; Baker LH; Benjamin RS; Canetta R
Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
[TBL] [Abstract][Full Text] [Related]
9. Imaging modalities in high-grade gliomas: pseudoprogression, recurrence, or necrosis?
Caroline I; Rosenthal MA
J Clin Neurosci; 2012 May; 19(5):633-7. PubMed ID: 22321359
[TBL] [Abstract][Full Text] [Related]
10. Response Assessment in Pediatric Neuro-Oncology: Implementation and Expansion of the RANO Criteria in a Randomized Phase II Trial of Pediatric Patients with Newly Diagnosed High-Grade Gliomas.
Jaspan T; Morgan PS; Warmuth-Metz M; Sanchez Aliaga E; Warren D; Calmon R; Grill J; Hargrave D; Garcia J; Zahlmann G
AJNR Am J Neuroradiol; 2016 Sep; 37(9):1581-7. PubMed ID: 27127006
[TBL] [Abstract][Full Text] [Related]
11. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
12. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.
Pirzkall A; Li X; Oh J; Chang S; Berger MS; Larson DA; Verhey LJ; Dillon WP; Nelson SJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):126-37. PubMed ID: 15093908
[TBL] [Abstract][Full Text] [Related]
13. Pseudoprogression and pseudoresponse in the treatment of gliomas.
Brandsma D; van den Bent MJ
Curr Opin Neurol; 2009 Dec; 22(6):633-8. PubMed ID: 19770760
[TBL] [Abstract][Full Text] [Related]
14. Contribution of diffusion tensor imaging to delineation of gliomas and glioblastomas.
Tropine A; Vucurevic G; Delani P; Boor S; Hopf N; Bohl J; Stoeter P
J Magn Reson Imaging; 2004 Dec; 20(6):905-12. PubMed ID: 15558549
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy.
Yang I; Huh NG; Smith ZA; Han SJ; Parsa AT
Neurosurg Clin N Am; 2010 Jan; 21(1):181-6. PubMed ID: 19944976
[TBL] [Abstract][Full Text] [Related]
16. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods.
Galanis E; Buckner JC; Maurer MJ; Sykora R; Castillo R; Ballman KV; Erickson BJ
Neuro Oncol; 2006 Apr; 8(2):156-65. PubMed ID: 16533757
[TBL] [Abstract][Full Text] [Related]
17. [Risk of increased malignancy a reason for follow-up of low malignancy grade glioma. Early identification of high-risk patients is the key to good care].
Smits A; Ribom D
Lakartidningen; 2000 Sep; 97(36):3886-90. PubMed ID: 11036339
[TBL] [Abstract][Full Text] [Related]
18. [Magnetic resonance spectroscopy in gliomas].
Galanaud D; Chinot O; Metellus P; Cozzone P
Bull Cancer; 2005 Apr; 92(4):327-31. PubMed ID: 15888389
[TBL] [Abstract][Full Text] [Related]
19. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.
van den Bent MJ; Wefel JS; Schiff D; Taphoorn MJ; Jaeckle K; Junck L; Armstrong T; Choucair A; Waldman AD; Gorlia T; Chamberlain M; Baumert BG; Vogelbaum MA; Macdonald DR; Reardon DA; Wen PY; Chang SM; Jacobs AH
Lancet Oncol; 2011 Jun; 12(6):583-93. PubMed ID: 21474379
[TBL] [Abstract][Full Text] [Related]
20. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
Jansen M; de Witt Hamer PC; Witmer AN; Troost D; van Noorden CJ
Brain Res Brain Res Rev; 2004 Jul; 45(3):143-63. PubMed ID: 15210301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
